AlphAIAlphAI — Financial news for AI agents
investing.com

Zealand Pharma Q3 underlying loss widens 70% as obesity drug costs surge

Zealand Pharma (CSE:ZELA) reported a 70% increase in Q3 underlying loss to 685M DKK due to rising obesity drug R&D costs, with revenue dropping to 4M DKK. A one-off gain from royalty rights sale reduced net loss to 54M DKK. The company narrowed its 2026 operating cost forecast but kept revenue guidance at 4.5B DKK. Phase 2 trials for petrelintide showed promising weight loss and blood sugar reduction results.

Original reporting
investing.com
Published Nov 12, 2026, 7:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 7:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ZLDPF
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

Med
01

Why it matters

The earnings miss and higher R&D spend suggest short-term downside pressure, but cost‑control measures could mitigate longer‑term risk.

02

Market read

Earnings release provides new data for traders; likely bearish for ZELA stock in the near term.

03

What to watch

Potential upside from upcoming EU decision on glepaglutide and Phase 3 milestones.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Zealand Pharma reported a widened Q3 underlying loss and updated operating cost guidance.

Market effects

Sector

Biotech sector may face pressure as loss highlights high R&D spend.

Regional

Danish market could see slight dip due to ZELA's results.

Global

Limited global impact; primarily affects investors in small-cap biotech.

Counterpoint

What could challenge this read

The narrowed cost forecast may support a rebound if upcoming trial data are positive.

Key entities

  • company
    Zealand Pharma

    Danish biotech developing obesity and rare disease drugs.

  • company
    Royalty Pharma

    Buyer of the rusfertide royalty rights.

Read at source← All news

Related articles

MedAI 8/10

Zealand Pharma's ZP9830 Shows Favorable Tolerability In Phase 1 Trial

Zealand Pharma (ZEAL.CO) reported positive Phase 1 trial results for ZP9830, an investigational Kv1.3 ion channel blocker. The trial showed favorable tolerability with no serious adverse events. The company plans further trials in plaque psoriasis and another autoimmune disease. ZEAL.CO shares are trading at DKK 221.50, down 2.12%.

rttnews.com
Med

Zealand Pharma generates metabolic therapeutics with AI platform

Zealand Pharma and Generate Biologics will collaborate to develop multispecific drug candidates using AI. Zealand will pay $30 million upfront, with potential milestone payments up to $1.2 billion. Zealand will handle clinical development and commercialization, while Generate leads research. The partnership aims to address unmet medical needs in cardiometabolic diseases.

bioxconomy.com
MedAI 8/10

Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate

Zealand Pharma and Generate Biomedicines partnered to develop protein-based obesity treatments, with a deal potentially worth $1.2bn. Zealand will pay $30m upfront and milestones, while Generate uses its AI platform for research. Zealand handles clinical development and commercialization. Generate's tech has also attracted deals from Amgen and Novartis.

finance.yahoo.com
MedAI 9/10

Generate Biomedicines, Zealand Pharma Strike $1.2B Deal

Generate Biomedicines and Zealand Pharma agreed to a $1.2B deal to develop protein-based treatments for metabolic diseases. Generate receives $30M upfront, with additional payments tied to milestones. Generate's shares rose 5% in extended trading. The companies will collaborate on two initial programs, with an option for a third. Zealand Pharma will handle clinical development and commercialization.

hoodline.com